NLS Global report

President Donald Trump announced on Monday January 20 that the United States will leave the World Health Organization (WHO).

IDRx is a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST.

This agreement grants Synthego a global license to manufacture and distribute AstraZeneca's novel CRISPR gene editing enzyme, eSpOT-ON, recently published as engineered ePsCas9, to the worldwide research community.

Stryker has announced a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical for USD 80 per share in cash, representing a total fully diluted equity value of approximately USD 4.9 billion.

Accumulus Synergy’s cloud-based data-sharing platform could accelerate access to vaccines and other health technologies by enabling multi-country regulatory submissions and expediting regulatory review and approval, potentially helping to end future emerging infectious disease outbreaks swiftly and more equitably.

All over the Nordics the innovative power is gearing up to put new products, therapies, and preventive measures on the market that will tackle Antimicrobial resistance (AMR) from various angles.